Shots:
- Cumberland has entered into an agreement to sell its portfolio of branded US products to an affiliate of Apotex for $100M in cash, which will create a platform to deliver specialty medicines
- The move separates Cumberland’s commercial business from its R&D operations, allowing the company to focus on advancing its pipeline product candidates post-closing, while also retaining its majority ownership in Cumberland Emerging Technologies
- Cumberland is evaluating ifetroban in a P-II study in systemic sclerosis, with enrollment complete & topline results expected, while a separate P-II trial in idiopathic pulmonary fibrosis is ongoing in the US with interim safety & efficacy data pending
Ref: PRnewswire| Image: Cumberland & Apotex | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
